Tekla Capital Management’s Editas Medicine EDIT Stock Holding History

Tekla Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-15,190	Closed	-$860K	–	181
2021 Q2	$860K	Hold	15,190	–	–	0.03%	172
2021 Q1	$638K	Buy	+15,190	New	+$865K	0.02%	187
2020 Q3	–	Sell	-130,201	Closed	-$3.85M	–	209
2020 Q2	$3.85M	Hold	130,201	–	–	0.15%	115
2020 Q1	$2.58M	Sell	130,201 -17,738	-12%	-$447K	0.12%	121
2019 Q4	$4.38M	Hold	147,939	–	–	0.17%	116
2019 Q3	$3.36M	Buy	147,939 +102,950	+229%	+$2.55M	0.15%	108
2019 Q2	$1.11M	Sell	44,989 -31,679	-41%	-$756K	0.05%	159
2019 Q1	$1.88M	Hold	76,668	–	–	0.08%	133
2018 Q4	$1.74M	Hold	76,668	–	–	0.07%	137
2018 Q3	$2.44M	Sell	76,668 -61,133	-44%	-$1.98M	0.09%	137
2018 Q2	$4.94M	Hold	137,801	–	–	0.19%	92
2018 Q1	$4.57M	Buy	+137,801	New	+$4.91M	0.18%	96

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Tekla Capital Management's EDIT Position: Q3 2021 in Review

Tekla Capital Management sold out of Editas Medicine (EDIT) in Q3 2021, closing a stake of 15,190 shares — an estimated $860K sold.

Tekla Capital Management first reported a position in EDIT in Q1 2018 and held it in 12 quarters. The position peaked at $4.94M in Q2 2018. 318 funds tracked by Wall St. Rank hold EDIT as of Q3 2021.

Tekla Capital Management reported no remaining Editas Medicine position as of Q3 2021 after selling out during the quarter.
Tekla Capital Management sold 15,190 Editas Medicine shares in Q3 2021, an estimated $860K.
Tekla Capital Management first reported a position in Editas Medicine in Q1 2018 and held it in 12 quarters.
Tekla Capital Management's Editas Medicine position peaked at $4.94M in Q2 2018.
318 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.